Advances in Rheumatology (Nov 2018)

Diffuse alveolar hemorrhage in childhood-onset systemic lupus erythematosus: a severe disease flare with serious outcome

  • Gabriela Blay,
  • Joaquim C. Rodrigues,
  • Juliana C. O. Ferreira,
  • Gabriela N. Leal,
  • Natali W. Gormezano,
  • Glaucia V. Novak,
  • Rosa M. R. Pereira,
  • Maria T. Terreri,
  • Claudia S. Magalhães,
  • Beatriz C. Molinari,
  • Ana P. Sakamoto,
  • Nadia E. Aikawa,
  • Lucia M. A. Campos,
  • Taciana A. P. Fernandes,
  • Gleice Clemente,
  • Octavio A. B. Peracchi,
  • Vanessa Bugni,
  • Roberto Marini,
  • Silvana B. Sacchetti,
  • Luciana M. Carvalho,
  • Melissa M. Fraga,
  • Tânia C. M. Castro,
  • Valéria C. Ramos,
  • Eloisa Bonfá,
  • Clovis A. Silva,
  • Brazilian Childhood-onset Systemic Lupus Erythematosus Group

DOI
https://doi.org/10.1186/s42358-018-0038-4
Journal volume & issue
Vol. 58, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Objective To evaluate prevalence, clinical manifestations, laboratory abnormalities and treatment in a multicenter cohort study including 847 childhood-onset systemic lupus erythematosus (cSLE) patients with and without diffuse alveolar hemorrhage (DAH), as well as concomitant parameters of severity. Methods DAH was defined as the presence of at least three respiratory symptoms/signs associated with diffuse interstitial/alveolar infiltrates on chest x-ray or high-resolution computer tomography and sudden drop in hemoglobin levels. Statistical analysis was performed using Bonferroni correction (p < 0.0022). Results DAH was observed in 19/847 (2.2%) cSLE patients. Cough/dyspnea/tachycardia/hypoxemia occurred in all cSLE patients with DAH. Concomitant parameters of severity observed were: mechanical ventilation in 14/19 (74%), hemoptysis 12/19 (63%), macrophage activation syndrome 2/19 (10%) and death 9/19 (47%). Further analysis of cSLE patients at DAH diagnosis compared to 76 cSLE control patients without DAH with same disease duration [3 (1–151) vs. 4 (1–151) months, p = 0.335], showed higher frequencies of constitutional involvement (74% vs. 10%, p < 0.0001), serositis (63% vs. 6%, p < 0.0001) and sepsis (53% vs. 9%, p < 0.0001) in the DAH group. The median of disease activity score(SLEDAI-2 K) was significantly higher in cSLE patients with DAH [18 (5–40) vs. 6 (0–44), p < 0.0001]. The frequencies of thrombocytopenia (53% vs. 12%, p < 0.0001), intravenous methylprednisolone (95% vs. 16%, p < 0.0001) and intravenous cyclophosphamide (47% vs. 8%, p < 0.0001) were also significantly higher in DAH patients. Conclusions This was the first study to demonstrate that DAH, although not a disease activity score descriptor, occurred in the context of significant moderate/severe cSLE flare. Importantly, we identified that this condition was associated with serious disease flare complicated by sepsis with high mortality rate.

Keywords